Tonix Pharmaceuticals (NASDAQ: TNXP) announced that the FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of Aug. 15, 2025, for a de ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 ...

Overview: Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases across the United States ...

The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United ...

Navenibart is a monoclonal antibody commercialized by Astria Therapeutics, with a leading Phase II program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency).

TNX-102 SL has the potential to be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug ...

Additionally, the Cambridge experiments showed that leukocyte esterase dipstick tests—one of the most common for UTI detection—work by highlighting neutrophils. It was long assumed that the ...

Counts are made from random fields of 200 to 500 cells. Esterase staining is often employed to distinguish immature macrophages from large lymphocytes. The number of ciliated or squamous ...

Dr. Kathleen M. McFadden (Medicine): A 22-year-old woman was transferred to this hospital in the summer before the coronavirus disease 2019 pandemic because of headache, fever, and respiratory ...

The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an ...